Point72 Asset Management L.P. Buys 218,143 Shares of Immunome, Inc. (NASDAQ:IMNM)

Point72 Asset Management L.P. increased its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 46.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 688,790 shares of the company's stock after acquiring an additional 218,143 shares during the period. Point72 Asset Management L.P. owned about 0.86% of Immunome worth $7,315,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IMNM. Enavate Sciences GP LLC bought a new stake in shares of Immunome during the fourth quarter worth approximately $36,939,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Immunome by 12.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company's stock valued at $24,243,000 after buying an additional 246,447 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Immunome by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company's stock valued at $13,054,000 after buying an additional 21,396 shares during the period. JPMorgan Chase & Co. boosted its holdings in Immunome by 2,540.4% during the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after purchasing an additional 624,045 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Immunome by 9.1% during the fourth quarter. Northern Trust Corp now owns 516,491 shares of the company's stock worth $5,485,000 after purchasing an additional 43,146 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall bought 137,100 shares of Immunome stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $7.29 per share, with a total value of $999,459.00. Following the transaction, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at $5,881,105.44. This represents a 20.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now directly owns 23,615 shares in the company, valued at $193,879.15. The trade was a 42.13% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 156,400 shares of company stock valued at $1,160,495 over the last three months. 8.60% of the stock is owned by company insiders.

Immunome Price Performance

NASDAQ:IMNM traded up $0.54 on Thursday, reaching $8.46. 803,042 shares of the company's stock were exchanged, compared to its average volume of 917,483. The firm has a market cap of $736.12 million, a price-to-earnings ratio of -1.04 and a beta of 2.00. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.81. The stock has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $9.72.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wedbush reaffirmed an "outperform" rating and set a $21.00 price target (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Lifesci Capital initiated coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target on the stock. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday. Lake Street Capital began coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price on the stock. Finally, Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.